Patient-reported outcomes from the phase 3 IMforte study of first-line maintenance treatment with lurbinectedin + atezolizumab versus atezolizumab in patients with extensive-stage small cell lung cancer

Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles